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Background: Nonpharmacological secondary prevention of coronary heart disease is considered a safe and
effective measure to substantially reduce mortality. Despite the effectiveness of lifestyle changes, the compliance
rate of patients is very low mainly due to psychosocial barriers. Psychotherapeutic approaches that address how
persons think about themselves and their behaviors appear to have a significant potential for improving health
behavior.
Methods/design: Against this background, our study aims to examine the feasibility and effects of a
Psychodynamic Motivation and Training program (PMT) as compared to one session of advice in exercise training
(EX) and treatment as usual (TAU). For that purpose, 90 patients with stable coronary heart disease and a physically
inactive lifestyle will be randomly assigned to the three groups (each with n = 30). The primary outcome is the
change in the individual anaerobic threshold as determined by spiroergometry from baseline to six month follow-
up. Secondary endpoints include change in endothelial function, biomarkers of inflammation and oxidative stress,
quality of life, symptoms of fatigue, illness perception and feasibility of the treatment approach. We hypothesize
that physical fitness will improve more in PMT than in EX and TAU, with PMT and EX more than TAU, and that the
effects will be more pronounced for participants with current mental or psychosocial distress.
Discussion: The results of the study will help to determine the effectiveness of a psychodynamic lifestyle change
approach and to identify measures for designing specifically tailored interventions to improve compliance with
cardiovascular prevention.
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Coronary heart disease (CHD) is the leading cause of
disability and death in Western societies. The prognosis
of established CHD is strongly influenced by lifestyle
factors such as smoking, unhealthy diet and physical in-
activity. Among those lifestyle risk factors, physical in-
activity is the most prevalent. In Europe, less than 50%
of the population is involved in regular aerobic leisure-
time, and/or occupational physical activity [1]. Regular
physical activity and aerobic exercise strongly reduce the
risk of fatal and non-fatal coronary events in patients
with CHD, buffer psychosocial distress and improve qual-
ity of life and symptoms of depression [2-5]. Therefore,
targeting physical inactivity is considered a very important
non-pharmacological tool for secondary cardiovascular
prevention. Accordingly, for persons with stable coronary
heart disease the European Heart Association strongly
recommends ‘moderate-to-vigorous intensity aerobic ex-
ercise training ≥ three times a week and 30 minutes per
session’; and ‘sedentary patients should be strongly en-
couraged to start light-intensity exercise … after adequate
exercise-related risk stratification’ [1].
The overall risk reduction by at least three months of aer-
obic exercise programs is around 30%. The positive effects
of aerobic exercise result from an improved ability to use
oxygen to derive energy for work [1], decreased myocardial
oxygen demands, improvement of myocardial perfusion,
antithrombotic effects, anti-inflammatory effects and anti-
arrhythmic effects by favorable modulation of autonomic
balance and improvement of endothelial function [1,2].
Despite its favorable effects, implementation of physical
activity recommendations has been proven highly prob-
lematic in daily life [6]. Psychological and socio-economic
factors have been identified as important barriers [7-9]:
economic disadvantage, overwork, family duties, feeling
physically restricted towards or fearful of exercise, lacking
knowledge regarding exercise, negative perceptions to-
wards health, lack of motivation and depression.
Psychotherapeutic strategies have been proven as crucial
components of lifestyle interventions, because the inter-
ventions need to address how persons think about them-
selves, their behaviors, and life circumstances [10]. The
more these essential components were addressed, the more
effective the interventions became [10]. The following
techniques were especially important [10]: clarification of
the goals and motivation of the individual, providing feed-
back and reinforcement for progress toward goal achieve-
ment, establishing peer-based support, strengthening self-
monitoring and self-efficacy. Of note, the authors of the
scientific statement of the American Heart Association
[10] labeled the above strategies as cognitive-behavioral,
however, considering current generic models of psycho-
therapeutic processes these are better described as general
psychotherapeutic strategies [11].Interestingly, the term ‘lifestyle’ was originally coined by
Alfred Adler (1870 to 1937), an Austrian medical doctor,
psychotherapist and founder of the psychodynamic school
of ‘Individual Psychology’. The ‘style of life’ refers to how
individuals live their life and how they handle problems
and interpersonal relations [12]. The individual lifestyle is
determined early in childhood by the individuals’ interper-
sonal and social experiences. Health behaviors like phys-
ical activity, smoking and dietary habits are essential
components of the individual lifestyle. The modern use of
‘lifestyle’ sometimes trivializes health behavior as it sug-
gests that an individuals’ lifestyle might be the result of
the individuals’ conscious decisions like choosing to buy a
certain brand of chocolate. However, this view neglects
the importance of biological, social, developmental, envir-
onmental, and psychological factors contributing to the
individual’s lifestyle [13-16]. Briefly, the effectiveness of
psychotherapeutic techniques as compared to mere pro-
vision of information demonstrates that mental factors
play a significant role for health behavior. There is already
consensus that this is true for smoking, which is regarded
as an addictive disorder in line with alcohol abuse or alco-
hol dependence. In similar ways, this may be also true to
some degree for eating behavior or physical activity.
The present study aimed to investigate the effective-
ness of a psychodynamic approach to health behavior
for secondary prevention of cardiovascular disease. To
our knowledge, up to date no psychodynamic treatment
studies have been explicitly targeting the improvement
of physical activity, respectively lifestyle improvement.
However, stronger recognition of lifestyle in psychother-
apy is an urgent need. Firstly, the detrimental effects of
depression on the development and outcome of coron-
ary heart disease are largely mediated by insufficient
physical activity and smoking [2,17-19]. Secondly, poor
health behavior is suggested to impair treatment out-
come of mental disorder itself [19]. Therefore, targeting
lifestyle change is considered to be a crucial component
of effective treatments [20]. According to our knowledge,
the ongoing stepwise psychotherapy intervention for redu-
cing risk in coronary artery disease (SPIRR-CAD, [21]) is
the only psychotherapy study, formulating explicitly health
behavior as a treatment focus. SPIRR-CAD was designed
to treat depression in patients with coronary heart disease.
The focus of the psychodynamic group psychotherapy also
included health behavior: there is one session of psy-
choeducation about modifiable cardiovascular risk factors
and each session of the group psychotherapy begins with
a brief statement of the patient about his feelings and
health behavior.
As psychodynamic psychotherapy is widely-used in
Western societies, it is desirable to develop psycho-
dynamic interventions suitable for lifestyle improve-
ment. Especially in Germany, family doctors and other
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provision of basic mental health care and many have
also been trained in psychotherapy for medically ill per-
sons according to psychodynamic principles.
This study aims to determine the feasibility of the new
treatment approach, to identify possible effects and ef-
fective components for designing specifically tailored in-
terventions to improve compliance with cardiovascular
prevention, respectively lifestyle change, that may be
worth following up in subsequent larger trials.Methods/design
Study center
The multidisciplinary single center randomized trial with
three parallel groups is carried out in collaboration among
the Departments of Cardiology, Psychosomatic Medicine
and Psychotherapy and Sports Medicine at the University
Medical Center of the University of Mainz.Table 1 Inclusion and exclusion criteria
Inclusion criteria:
1. Stable coronary heart disease with CCS functional
classification of angina class I to III
2. Low self-rated physical activity
3. Condition after percutaneous coronary intervention >
4 weeks until < 26 weeks or > 52 weeks after index
percutaneous coronary intervention
4. Residence < 50 km radius of the study center (city
of Mainz)
5. If treatment with beta blockers or ivabradine then
stable > 4 weeks
Exclusion criteria:
1. Acute coronary syndrome or myocardial infarction
< 8 weeks
2. Coronary stenosis of the dominant vessel > 25% or
high grade stenosis of the left coronary artery
3. Heart failure with left ventricular ejection fraction
< 40%
4. NYHA III to IV
5. Severe heart valve disorder
6. Insulin dependent diabetes
7. Orthopedic or other disorders, which preclude
regular physical activity
8. Coronary artery bypass surgery < 6 months
before index PCI
9. Severe obesity (BMI≥ 40)
10. Need for systemic immunosuppression with
cortisone or methotrexate
11. Kidney failure with need for dialysis
12. Intake of nitrates < 12 hours
CCS severity of angina according to the Canadian Cardiovascular Society, NYHA
symptoms of heart failure according to the New York Heart Association, PCI
percutaneous coronary intervention.Participants
Patients are eligible to participate if they fulfill the fol-
lowing criteria: age between 18 to 75 years, stable coron-
ary heart disease determined by percutaneous coronary
intervention and low physical activity.
Patients are recruited from the Department of Cardi-
ology of the University Medical Center Mainz and pri-
vate practices of general practitioners and cardiologists,
by research advertisement in the local newspapers and
announcements on the webpage of the University Med-
ical Center. Further, patients who were hospitalized for
percutaneous coronary intervention during the last ten
years are actively approached with an information letter.
Once a patient articulates his interest in participation,
he signs an informed consent allowing the inspection of
any medical records and screening for physical activity.
The individuals’ medical records are reviewed for the in-
clusion and exclusion criteria by a research assistant and
a medical doctor. Low physical activity was defined as
less than 15 to 20 minutes of at least moderate exercise
training per week during the last month according to
the definition of the Heart and Soul Study [17]. This
criterion was a strong predictor of mortality in post-
myocardial patients [17]. After the review of the medical
records, the patient is contacted, usually by phone, and
interviewed for inclusion and exclusion criteria. Further,
he receives information about the procedures and aims
of the study. If the patient is eligible and willing to par-
ticipate, he/she is invited to the study center for further
information. After discussion of the study procedures,
he/she is asked to sign the informed consent for trial
participation. Participating patients are paid an allow-
ance of €25 for the baseline assessment and €75 for the
follow-up assessment.Table 1 lists the inclusion and exclusion criteria. Inclu-
sion and exclusion criteria were selected based on the
following considerations: firstly, in order to ensure a
valid diagnosis of coronary heart disease, a percutaneous
coronary intervention was required. Secondly, in order
to keep the threshold for participation low. Thirdly, in
order to be able to analyze biological outcome parameters
such as inflammation, endothelial function and anaerobic
threshold. For the latter purposes, the participants should
not be treated with insulin or systemic immunosuppres-
sant drugs. Changes in medication with beta-blockers,
statins and drugs acting on the renin-angiotensin axis in
the last two weeks before each planned visit were not
allowed (that is, visits were rescheduled).
Interventions
The study has three arms, two active arms and the
control condition ‘treatment as usual’. The active arms
added to the control condition ‘treatment as usual’.
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Treatment as usual (TAU) comprises regular treatment
by the general practitioner, including standard lifestyle
recommendations, cardiological and any other health care
utilization by the patient. As in Germany all persons have
full insurance coverage for medical care including long-
term outpatient psychotherapy, TAU represents ‘optimal
medical care’.
Advice in exercise training
The second arm consists of one session of detailed and
individualized advice in exercise training (EX). Counsel-
ling by an experienced sport medicine specialist is based
on the findings of the present spiroergometry and the
review of the medical records. The participant receives
an exercise-plan with recommendations of endurance
exercise time or resistance training based on guidelines
for adults from the American College of Sports Medi-
cine and the American Heart Association [22] and indi-
vidual heart rate range in two different intensities of
training for aerobic exercise activity.
Psychodynamic motivation and training program
The Psychodynamic Motivation and Training program
(PMT) follows a psychodynamic stepped care approach.
It consists of two to eight sessions of individual psycho-
dynamic psychotherapy in addition to EX. Session fre-
quency, mode (for example. face-to-face consultation,
telephone) and dosage are tailored to the individual needs.
The maximum dosage is limited to 400 minutes per pa-
tient over six months. The individual need is determined
by the regular monitoring of physical activity and the
patients’ wishes. PMT is conducted by a psychodynamic
psychotherapist (board certification or supervision by cer-
tified psychotherapist).
PMT is a psychodynamic stepped treatment approach
integrating components that have been proven effective
for lifestyle change [10] and stress regulation (for ex-
ample. mindfulness exercises, [23]). The stance of the
psychotherapist is actively engaged, goal-directed and
directive as described in current manuals of short term
psychodynamic psychotherapy [24]. The therapist is will-
ing to teach and guide the patient. The therapist identi-
fies negative transference issues immediately, so that
they can be worked through as soon as they arise. Every
effort is done to establish the necessary alliance and
trust in the therapeutic relationship. As intellectual
insight into the need of improved health behavior and
the readiness to change are quite separate issues, the
therapist must help the patient to experience the bene-
fits of his adaptive wishes and the costs of his maladap-
tive behavior emotionally. PMT targets the mental and
external barriers to improving physical activity by focus-
ing on affects, interpersonal relations and self- and otherrepresentations. Unhealthy behavior is considered as the
result of maladaptive self-representations (that is, lack of
self-care due to blocked positive feelings toward the self )
and dysfunctional capacities of anxiety respectively stress
regulation (for example, stressful overeating, smoking,
addictive television watching, blocked assertiveness to
pursue one’s goals). The intervention aims at motivating
the patient to be more caring about himself as reflected
in improved health behaviors, especially in a physically
more active way of living. Physical activity is defined as
daily life activities (walking instead of driving, staircase
instead of elevator and so on) and home-based exercise
training of moderate or vigorous intensity (for example,
jogging, swimming, participating in coronary exercise
groups, or supervised endurance and weight training).
The first session starts with the questions ‘What moti-
vated you to participate in this study?’ and ‘What about
the recommendations of the sport medicine specialist,
how have you succeeded in following them?’. These
questions give a good introduction into the discussion of
the relevant themes. The aims of the first sessions are to
establish a secure therapeutic alliance, to take a bio-psycho
-social history, to identify maladaptive health behaviors, as-
sess subjective illness concept and disease knowledge,
manner of health care utilization and predominant coping
strategies. Further, inner resistance (lack of motivation,
hopelessness and so on), lack of knowledge, external
barriers (lack of time, financial problems), and resources
(partnership, neighborhood, personal strengths) towards
realizing a more physically active style of living are ex-
plored. On the basis of this dialogue, an individual health
plan is designed together with the patient. The health plan
follows the structure of ‘My Better Health Plan’ as de-
scribed in the TEAMcare Intervention Manual [25]. The
health plan consists of the goals of the patient, the mea-
sures to achieve this goal, a point-to-point to-do-list, ex-
planatory notes on mental barriers towards following the
to-do-list and the date of the next visit for monitoring the
targets. Table 2 gives an example of a personalized health
plan of the first session from the patient Mrs. A of vignette
1 (Additional file 1). To note, for the collaborative design
of the ‘Health Plan’ it is not sufficient that the patient for-
mulates his wish to improve his fitness in order to live lon-
ger. It is very important that the patient can imagine the
benefits of improved health behavior vividly with a sense of
positive feelings and hope. These positive emotions need
to be labeled and validated. The health plan and a copy of
the ‘National Patient Guideline Coronary Heart Disease’
are handed to the patients.
Vignette 2 describes a patient Mr. B. with less need for
psychotherapeutic support (Additional file 2). During
the follow-up sessions the health plan is monitored and
individually adapted to the patients’ needs. In each ses-
sion, internal and external barriers and the individual
Table 2 Health plan
My goals I want to improve my health, my physical and cognitive fitness, in order to preserve my autonomy,
because I enjoy living. I want to spend more years with my son and his wife and I am looking
forward to become a grandmother and see my grandchild grow up.
The measures to achieve my health goals 1) I need to be more physically active, at least 150 minutes and at best 300 minutes of moderate
exercise training per week; 2) I need to quit smoking urgently; 3) I need to care more about myself
(for example, meet friends and do things that I enjoy such as traveling and cinema/theater);
4) I need to improve my dietary habits (less alcohol, less chocolate, more fruits and vegetable).
My to-do-list 1) 20 minutes brisk walking at pulse range of 90 to 105 beats per minute every second day; 2) I will
reflect on my reasons for smoking and try to become more aware of the harm I cause to the most
important goals in my life; 3) I will carefully read the patient guideline for coronary heart disease
and reflect about it.
Potential obstacles I am in danger of missing good opportunities for engaging myself for important goals due to
maladaptive feelings of guilt. These guilt feelings block healthy impulses, for example, doing what I
like, assertiveness, and taking a long-term perspective on my life.
Check-up Date of next visit.
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physical activity, the aim is to increase the dosage of
exercise training to 300 minutes of moderate or 150 mi-
nutes of vigorous training per week as recommended by
the medical guidelines. In the second session, the read-
ing assignment of ‘National Patient Guideline Coronary
Heart Disease’ is reviewed: ‘Did any questions arise?
What were your feelings regarding this guideline?’ Some-
times patients report that the reading of the guideline
elicited anxieties. This occurs especially in patients who
tended to deny that they have a chronic disease. After
reading the guideline they recognize that coronary ar-
teriosclerosis is not cured by coronary angioplasty, but
lifestyle change and long-term coping strategies are re-
quired. The review of the reading assignment is followed
by the exploration of medical risk factor control and ad-
equate health care utilization (‘Do you regularly measure
your blood pressure? Is your blood pressure below 140/
90 mmHg?’; ‘Do you know your cholesterol levels? Is
your LDL below 100 mg/dl?’). If problems are identified
the patient is encouraged to consult his general practi-
tioner for engaging in target control.
In the second or third session, an offer is also made to
the patient to include his/her partner into treatment
with the purposes of information and improvement of
social support for establishing a healthy style of life. In
addition to the treatment targets physical activity and
health behavior, the patient is encouraged to speak about
all other issues that bother him. These psychosocial issues
concern mainly difficulties with the partner, stress at work
or stress of taking care for family members, and difficulties
with communicating their needs to their doctors.
If a mental disorder is identified during the course of
the treatment, the patient is informed about treatment
options according to the current medical guidelines.
Psychopharmacotherapy may be initiated during the trial.
If there is need for further psychotherapy, the patient willreceive specific recommendations and information how to
obtain this.
Assessment
The assessment includes spiroergometry, blood and
urine sampling, measurement of endothelial function
and psychometric questionnaires at baseline (T0) and six
months follow-up (T1). Spiroergometry, anthropometry
and blood sampling are conducted in the Department of
Sport Medicine of the University Mainz. Measurement
of endothelial function, blood pressure measurement,
blood and urine sampling are performed in the Depart-
ment of Cardiology. Assessors are blinded to the alloca-
tion of the patients. Medical diseases and medications
are captured by the review of recent medical records
and patient interview. Figure 1 gives an overview of the
study design and time points of assessment.
Spiroergometry
The spiroergometry is performed on a bicycle ergometer
according to a standardized protocol. Ergometry is
carried out in supine position on a computer-controlled
bicycle ergometer (Ergoselect 200P, ergoline GmbH,
Bitz, Germany). The ergometry protocol starts at 20, 25
or 50 Watts depending on the expected maximal work
load and is increased by 20 or 25 Watts every three mi-
nutes. The patients are instructed to keep a pedal rate
of 60 rpm. A 12-lead electrocardiograph (ECG) is con-
tinuously recorded. Non-invasive blood pressure is
measured before exercise, at the beginning and end of
every stage, and three and six minutes after exercise.
Heart rate is registered continuously by ECG. Oxygen
uptake (VO2), CO2 output (VCO2), and minute venti-
lation (VE), are measured with an open system spirom-
eter (Ergostick, Geratherm Respiratory, Bad Kissingen,
Germany). The respiratory parameters are measured
breath-by-breath, starting one minute before and ending
Screening for eligibility
Stable coronary artery disease class ascertained by percutaneous coronary intervention and physically inactive, age 18-75, 
review of medical records, check for inclusion and exclusion criteria, informed consent. 
Baseline assessment
Primary outcome: Individual anaerobic threshold as determined by spiroergometry
Secondary outcome: Endothelial function, biomarkers of inflammation and oxidative stress, change in self rated physical 
activity,  quality of life, vital exhaustion, fatigue and illness perception, etc.
Randomized allocation to 3  groups with n=30 participants
TAU EX
1 session advice in exercise training 
based on the spiroergometry
PMT
Psychodynamic psychotherapy in addition 
to EX with 2 to 8 sessions (maximum 
dosage 400 minutes)
6 month follow-up (T1) 
Assessment of the primary and secondary outcome variables according to T0
Figure 1 Study design.
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averaged over consecutive intervals of three seconds.
Patients are advised to cycle until complete exhaustion.
Exercising is stopped if one of the following symptoms
occurs: chest pain, ST-segment depression, ventricular
arrhythmias, systolic blood pressure > 250 mmHg or
diastolic blood pressure > 115 mmHg, or a drop in
blood pressure.
Lactate is measured at rest and following each work-
load stage and three and six minutes after exercise by
taking capillary blood samples from the hyperemic ear-
lobe. The individual anaerobic threshold (IAT) is deter-
mined from the lactate curve by determination of the
relative work load (Watt/kg) when a 1 mmol rise in lac-
tate can be found above the minimum lactate equivalent
[26,27]. The ventilatory threshold (VT) is determined by
analysis of the increase in the respiratory equivalent for
oxygen or by decrease in the respiratory equivalent for
carbon dioxide [28]. The V-slope method [29] and typ-
ical changes in end-tidal gas concentrations (PETO2 and
PETCO2) are examined to search for agreement to con-
trol for precision of VT determination.Endothelial function
Endothelial function is a valid surrogate marker for car-
diovascular disease. The extent of endothelial dysfunc-
tion appears to reflect the traditional risk factor burden
[30]. The methods employed for the analysis of endothe-
lial function using flow-mediated dilation and constric-
tion (FMD and L-FMC) have been previously published
[31]. Briefly, L-FMC and FMD are measured using a
Vivid 7 (General Electrics, Munich, Germany) ultra-
sound platform equipped with a 14 MHz matrix probe
and a micrometric probe holder. L-FMC is defined as
the constriction observed in the last 30 seconds of a
4.5 minute occlusion of a pneumatic cuff placed distal to
the site of arterial diameter measurement and provides
information on resting endothelial function. FMD is
measured as the maximal dilation observed in the five
minutes following deflation of the cuff, that is, during re-
active hyperemia, and corresponds to endothelial re-
sponsiveness or recruitability. Both markers have been
shown to be blunted in the setting of coronary artery
disease, hypertension, heart failure, and after smoking
[32]. Arterial diameter data are acquired digitally and
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matic dedicated software whose repeatability and repro-
ducibility has been recently reported [33]. Flows will be
analyzed from the digitized audio data using the auto-
mated software built in the ultrasound machine.
Blood pressure measurement
Blood pressure will be assessed by a trained research assist-
ant (blinded to treatment), using the auscultatory method,
with a calibrated sphygmomanometer and stethoscope.
Anthropometry
Anthropometry includes assessment of height and weight,
waist-to-hip ratio (WHR) and determination of body com-
position (body fat, muscle mass, intracellular and extracel-
lular water) by the InBody 3.0 system (Biospace Ltd. 1999)
518–10 Dogok 2-dong, Gangnam-gu, Seoul, 135–854
Korea; http://www.e-inbody.com/.
Blood and urine sampling
Humoral markers will be obtained from fasting blood
samples. Serum lipid levels (total cholesterol, triglycer-
ides, and high-density lipoprotein cholesterol), plasma
levels of C-reactive protein, fibrinogen, albumin levels
and HbA1c are measured immediately after blood with-
drawal by routine methods; low-density lipoprotein chol-
esterol will be calculated by the Friedewald formula.
Markers of oxidative and inflammatory stress will be de-
termined in plasma or serum stored immediately after
blood withdrawal and centrifugation at −80°C until ana-
lysis. The measurements will be done in a blinded fash-
ion in a single batch.
Psychometric questionnaires
Quality of life is assessed by the EQ-5D™ (EuroQuol
Group, Rotterdam, Netherlands) [34]. The EQ-5D™ cap-
tures problems pertaining to usual activities and anxiety/
depression dimensions, and the respondent’s own assess-
ment of their health status on a visual scale from 0 (worst
imaginable health) to 100 (best imaginable health). Coron-
ary artery disease related quality of life is measured with
the Seattle Angina Questionnaire (SAQ) [35].
Feelings of vital exhaustion are assessed by the Maas-
tricht Questionnaire [36] and symptoms of fatigue by
the MFI Multidimensional Fatigue Inventory (MFI) [37].
Insomnia symptoms were measured by the Jenkins
sleep questionnaire [38], covering difficulties initiating
and maintaining sleep as well as non-restorative sleep.
Occurrence of sleep disturbances is rated for the previ-
ous four weeks from: not at all (1), 1 to 3 days (2), 4 to
7 days (3), 8 to 14 days (4), 15 to 21 days (5) to 22 to
28 days (6).
The cognitive and emotional representations of the
coronary heart disease are measured by the brief IllnessPerception Questionnaire (IPQ) [39]. Changing patients’
illness perceptions may improve outcome in coronary
heart disease [40].
Self-rated habitual physical activity was measured by
the Habitual Physical Activity Questionnaire [41] and
the one item screener from the Heart and Soul Study
[17]: ‘Which of the following statements best describes
how physically active you have been during the last
month, that is, done activities such as 15 to 20 minutes
of brisk walking, swimming, general conditioning, or
recreational sports?’ Participants chose from one of the
following six categories: not at all active, a little active (1
to 2 times per month), fairly active (3 to 4 times per
month), quite active (1 to 2 times per week), very active
(3 to 4 times per week), or extremely active (≥ 5 times
per week). Being ‘not at all’ or ‘a little’ active is consid-
ered as physically inactive.
Different dimensions of mental distress are assessed by
the Patient Health Questionnaire (PHQ) [42]: depres-
sion, anxiety, somatic symptoms and ten common psy-
chosocial stressors. The depression module comprises
nine symptoms of depression (PHQ-9). The scores range
from 0 to 27. A cut-off ≥ 10 yields a sensitivity of 81%
and a specificity of 82% for detecting any depressive dis-
order [43]. Anxiety is assessed by the Generalized Anx-
iety Disorder Scale (GAD-7) [44]. Scores range from 0
to 21 with higher values reflecting more anxiety. Somatic
symptoms severity is assessed with the 15 items of the
PHQ-15. Scores range between 0 to 30. Scores above 15
identify individuals with high levels of somatic symptom
severity respectively somatization severity [45]. In addition
to symptoms of mental disorders, the PHQ assesses con-
cerns about ten major psychosocial stressors (for example,
financial status, family relationships, work, health) on a
three-point scale (not bothered, bothered a little, bothered
a lot) [42]. For the determination of a subgroup of persons
with increased mental or psychosocial distress, the follow-
ing scores will be calculated: item #3 of the PHQ-9 will be
used as a screener for sleep disturbances as a previous
study found that the sleep disturbance item correlated
strongly with the well-validated Insomnia Severity Index
[46]. Sleep disturbances more than half the days will be
determined as significant. Clinically significant anxiety will
be determined by the two-item version of the GAD-7 [47]
with a cut-off score of three or more [48]. The two-item
depression module of the Patient Health Questionnaire
(PHQ-2) will be calculated also [47]. As in a previous
study a PHQ-2 score of two or more predicted the mor-
tality of patients who underwent PCI, we applied this
cut-off [49].
Cognitive functioning
After having started the recruitment for the study we de-
cided to include a computer based version of the Tower
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changes of cognitive functions. The Tower of London
(ToL) is a frequently used neuropsychological test instru-
ment for assessing planning ability in various clinical and
healthy populations [51]. In its original version, three balls
of different colors are placed on three different rods of dif-
ferent lengths [52] and subjects are presented with a start
state and instructed to transform it into a given goal state.
In order to solve the problem in the least possible number
of moves, subjects are thus requested to plan ahead a so-
lution before manually executing the moves. Three rules
have to be followed: (i) only one ball can be moved at a
time, (ii) balls must not be placed outside the tower, and
(iii) if more than one ball is stacked on a rod, only the top-
most ball can be moved.
The ToL problem-set applied in the study consists of
an optimized problem selection using eight four-, five-,
and six-move problems each of which instantiate a linear
increase of problem difficulty [53]. Test duration was
limited to a maximum of 20 minutes. The test has been
proven responsive to exercise interventions [54,55]. We
estimate that 30 complete measurements will be avail-
able at study finalization.
Objectives and hypotheses
The purpose of this study is to examine the effectiveness
of the Psychodynamic Motivation and Training program
(PMT) for the improvement of physical fitness as deter-
mined by the individual anaerobic threshold in patients
with stable coronary heart disease as compared to one
session of advice in exercise training (EX) only, or treat-
ment as usual (TAU). We have the following hypotheses:
1) PMT is more effective than EX only and TAU
concerning change in individual anaerobic threshold.
2) The advantage of PMT will be more pronounced for
persons with current mental distress and
psychosocial stressors as compared to persons
without such stressors.
3) Both active interventions (PMT, EX) are more
effective than TAU concerning change in individual
anaerobic threshold and secondary endpoints.
4) PMT will be more effective in improving illness
perception, quality of life and symptoms of
psychosocial distress than EX or TAU.
Outcomes
The outcomes are determined by change from baseline
to six month follow-up. The primary outcome is change
in power (Watt/kg) at the individual anaerobic thresh-
old according to lactate kinetics during spiroergometry.
Although the maximal oxygen uptake (VO2−peak) is
currently the most popular risk stratification factor for
patients with coronary heart disease, we decided todetermine the individual anaerobic threshold as our
primary outcome. It is well known that assessment of
VO2−peak is limited by the ability of patients to engage
in maximal exercising and influenced by their motiv-
ation and perceived exertion. Therefore, submaximal
reference values of exercise capacity, like oxygen uptake
at the ventilatory threshold (VT), have been demon-
strated to be more objective [56]. Submaximal exercise
values such as VT and ventilatory efficiency have been
described as better predictors for mortality or major
cardiac events than VO2-peak [57,58]. The concept of
the lactate threshold for the determination of training
loads is a method for endurance performance assess-
ment and for the prescription of exercise intensities that
is valid and reliable [59]. Particularly, individual anaer-
obic thresholds (IAT) determined by lactate kinetics in
graded exercise treadmill protocols have been described
to have an even higher test-retest reliability then the de-
termination of the ventilator threshold [26].
More recently, a two-month residential rehabilitation
program, including exercise training in patients with
chronic heart failure, revealed that all exercise intensity
related values at the IAT including VO2, VCO2, work
rate in Watts, and VE were much more significantly im-
proved than the respective values at maximal exertion
[60]. We therefore decided to determine the IAT as main
outcome variable in our intervention using a graded exer-
cise protocol as developed by Dickhuth and co-workers
[26] that is adjusted and validated for cycling [27].
Secondary outcomes are change in maximal aerobic
capacity (VO2−peak); change in endothelial function
according to the flow mediated dilatation; change in
high-density lipoprotein levels; change in biomarkers of
inflammation and oxidative burst; change in the waist-
to-hip ratio and body mass index (BMI kg/m2) as deter-
mined by supervised medical anthropometry; change in
the self-rated habitual physical activity according to the
Habitual Physical Activity Questionnaire; change in
quality of life according to the visual analog scale of the
EQ-5D; change in the severity of impairment by angina
symptoms according to the Seattle Angina Question-
naire; change in fatigue according to the Maastricht
Questionnaire; change in quality of sleep according to
the Jenkins Sleep Questionnaire; and change in illness
perception according to specific items from the brief Ill-
ness Perception Questionnaire (item #1 ‘consequences
score’; item # 3 ‘personal control’ and item # 6 ‘illness
concern’). In a subgroup of participants, we will further
be able to explore change in performance of goal plan-
ning according to the ToL.
Feasibility of the intervention will be assessed by analyz-
ing procedures for recruitment (ratio of patients screened
versus included), acceptability of allocation procedures
and attrition rates (loss to follow-up measurements,
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the dosage of PMT will be described by minutes and mode
of intervention.
Sample size calculation
As this is the first study on the effectiveness of a psycho-
dynamic motivation and training program, we designed
the study primarily to test the feasibility of PMT and
possible effects that may be worth following up in a subse-
quent larger study. The sample size calculation was based
on the following considerations: in general, exercise pro-
grams for patients with CHD yield increases in the aerobic
capacity as determined by the VO2-peak of 2.6 ± 1.6
(mean ± standard deviation) versus 0.3 ± 1.4 mL/kg/min in
the inactive control groups [61]. This difference corre-
sponds to an effect size of about 1.5 standard deviations.
With regard to change of the anaerobic threshold, a recent
study on the effects of exercise training in patients with
chronic heart failure found at the lactate threshold, a mean
workload difference of 43 Watts with a standard deviation
of about 17 Watts [60]. For our study we estimated a 50%
lower effect size differences, as the exercise training was
not supervised and therefore presumably less intensive.
Comparing PMT to EX and to TAU, while controlling
the multiple type one error at a level of 0.05, each com-
parison has to be performed at the nominal level of 0.025
using the Bonferroni correction. With a sample size of n =
30 in each group, a standardized effect size of 0.82 can be
detected at the two-sided level 0.025 with a power of 0.80.
Assuming that the standard deviation of change in the in-
dividual anaerobic threshold is 17 Watts (which is roughly
in accordance with results from [60]), this corresponds to
an absolute effect of 14 Watts for PMT, which is less than
half of the effect reported in [60].
Randomization
The participants are randomized to three groups with n =
30 patients each. A computer program randomly assigned
numbers from 1 to 90 to three sets representing the three
groups. The numbers were hidden in closed envelopes.
For each new participant an envelope was opened and the
participant was allocated accordingly.
Statistical methods
Categorical variables are presented as frequencies and per-
centages (n,%), continuous variables as means and standard
deviations (mean ± standard deviation), or medians and
quartiles for variables with skewed distributions (median
(25th quartile, 75th quartile). Baseline characteristics of the
three treatment groups will be compared with respect to
age, sex, socioeconomic status, partnership, cardiovascular
risk-factors (for example, smoking, obesity), comorbidity,
variables characterizing patients with coronary heart dis-
ease (for example, medication) and outcome parameters.Primary and secondary endpoints will be analyzed
according to the intention-to-treat principle. Change from
baseline to follow-up will be analyzed by analysis of covari-
ance adjusting for baseline measurement of the respective
outcome. Doing so, separate contrast are specified for
comparing PMT with EX and TAU, respectively. Cohen‘s
effect size will be calculated. In order to determine whether
the effect of PMT is modified by presence of significant
mental distress and psychosocial stressors at baseline, a test
for interaction will be performed. Exposure to significant
mental distress and psychosocial stressors will be de-
fined by at least one of the following baseline criteria:
PHQ-2 ≥ 2, GAD-2 ≥ 3, sleep disturbances (according to
item #3 of the PHQ-9 ≥ ‘more than half the days’), and
common psychosocial stressors according to the PHQ
module (‘being bothered a lot’ by ‘difficulties with hus-
band/wife, partner/lover or boyfriend/girlfriend’, or
‘stress of taking care of children, parents, or other family
members’, or ‘stress at work outside of the home or at
school’, or ‘having no one to turn to when you have a
problem’). All analyses will be conducted on a two-sided
level of significance with P < 0.05.
Ethical issues
The final study protocol and the final version of the writ-
ten informed consent form were approved by the Ethics
Committee of the Federal State of Rhineland Palatine in
Germany (ref: 837.274.11.7816). The procedure set out in
this protocol, pertaining to the conduct, evaluation, and
documentation of this trial, were designed to ensure that
all persons involved in the trial abide by the code of Good
Clinical Practice and the ethical principles described in
the current revision of the Declaration of Helsinki. The
trial will be carried out in keeping with local legal and
regulatory requirements. Before being admitted to the
clinical trial, patients must consent to participate after the
nature, scope, and possible consequences of the clinical
trial have been explained in a form understandable to
them. The patients must give written informed consent to
participate in the study, including their consent to publish.
Any findings during the study assessments that need fur-
ther clarification are communicated to the patient by a let-
ter with specific recommendations. For example, if there
are clinically significant depressive symptoms, the patient
will be informed about this finding with the recommenda-
tion to consult his general practitioner for further diagnos-
tic evaluation and treatment. The participating patients
are paid an allowance of €25 for baseline assessment and
€75 for the follow-up assessment.
Discussion
According to our knowledge, this is the first study inves-
tigating effects of psychodynamic psychotherapy on car-
diorespiratory and physical fitness. We hope that the
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intervention an individual patient needs, respectively
which patients profit from such individualized treatment
approaches, and for who personalized exercise advice
or even treatment as usual might be sufficient. As this
study focused primarily on motivational barriers for life-
style improvement, no supervised exercise training was
applied. Home based exercise training was considered as
the appropriate mode, as this keeps the threshold for
participation lower as opposed to structured supervised
exercise training with regular schedules. Important
strengths of the study are the use of biological outcome
parameters. Changes in the individual anaerobic lactate
threshold and oxygen consumption are much more reli-
able measures of improved physical activity than self-
reported increases in physical activity. Further, by ana-
lyzing change of endothelial function we will be able to
describe effects on an important surrogate parameter of
cardiovascular disease.
A major limitation of the study is the short duration of
observation. The investigation of the sustainability of ex-
ercise and life style compliance needs at least one or
more years of observation. Another important limitation
concerns the recruitment of participants. As the partici-
pants need to give their informed consent to participate
in this trial, we expect that the vast majority of the pa-
tients are already at the stage of contemplation about
the necessity to improve their physical activity. This is to
say, we will not be able to recruit pre-contemplative pa-
tients [62,63]. These latter pre-contemplative patients,
however, will presumably have the most severe lifestyle
problems as they are even not emotionally aware of the
detrimental consequences of their behavior. These pa-
tients actually represent a target population of our psy-
chodynamic approach, as psychotherapy especially helps
to build up motivation, for example, by helping to ex-
perience emotionally the costs of one’s maladaptive be-
havior. Due to this selection-bias, inferences from our
study to pre-contemplative patients will be restricted.
Trial designs have to be developed that enable both in-
formed consent and inclusion of ‘unwilling’ patients.
Further limitations comprise the lack of a more elabo-
rated assessment of blood pressure (for example, home
or ambulatory blood pressure measurements at regular
intervals). Due to this lack, the analysis of effects on
high blood pressure is limited. However, blood pressure
at baseline and follow-up will be considered as a poten-
tial confounder of the endpoints. If adequate, additional
adjustment for blood pressure will be applied. Another
limitation is the lack of the assessment of endothelium-
independent vasodilatation [64-66]. However, a number
of studies showed no effect of exercise on nitroglycerin
(endothelium-independent) responses, at least in the
forearm circulation, and that these responses were notassociated with VO2−peak levels [67]. Last but not least,
differences in the initiation of psychopharmacotherapy
may constitute a potential bias regarding secondary
endpoints such as fatigue and quality of life. In order to
be able to control for this potential bias, the rate of
psychopharmacotherapy will be assessed at baseline
(current) and at follow-up (past, current).
Trial status
Recruitment of participants is ongoing. The first partici-
pant was included in October 2011. We expect that the
last patient will have finished by May 2014.
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